Aaron Goodman is an Oncology physician. OpenAlex indexes 190 publications with 12,047 citations (h-index 35).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3150 N Tenaya Way Ste 320
Las Vegas, NV 891280447
Telephone
702-962-2100Provider last certified this registry record 2 Oct 2025.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202551 payments$42,129openpaymentsdata.cms.gov ↗
- Rigel Pharmaceuticals, Inc.Program year202510 payments
- Medexus Pharma, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
30.8%Kinase inhibitor18.7%Jakafi29%Brukinsa26%Sprycel18%Cotellic14%Imatinib Mesylate13%Part D<11 patientsThalidomide Analog12.1%Revlimid67%Lenalidomide33%Part D<11 patientsDermatology
17.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor17.7%Acyclovir100%Part D≥25 patientsMetabolism & gastrointestinal
15.8%Proton pump inhibitor6.4%Omeprazole100%Part D<11 patientsSerotonin-3 Receptor Antagonist5%Ondansetron Hcl100%Part D≥15 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Dietary interventions in cancer: a systematic review of all randomized controlled trials
JNCI Journal of the National Cancer Institute
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”